MAIA Biotechnology, Inc. MAIA
1.05 USD -0.04 (-3.67%)
At closeNov 10, 2026, 4:00 PM EST
1.07 +0.02 +1.90%
After hours · Nov 10, 4:00 PM ET
1.05 Day range 1.12
0.87 52-week range 3.19
- YTD
- -31.37%
- 1 year
- -8.70%
News
benzinga.com Alpha Buying: 4 Biotech Stocks Insiders Are Betting On I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
benzinga.com MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached…
globenewswire.com MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
globenewswire.com Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology,…
youtube.com MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that looks like a ‘Muse'-style assistant for workplace use. He notes that the company's push suggests the…
benzinga.com MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder")…
benzinga.com MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer THIO-104 advances toward key 2027 interim survival analysisCHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
globenewswire.com MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage…
globenewswire.com MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed…
benzinga.com MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3…
globenewswire.com MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies- benzinga.com MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock…
globenewswire.com MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies…
youtube.com MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressure, pointing to broad measures of nominal wage inflation that have been decelerating. She argued…
globenewswire.com MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American:…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…
globenewswire.com Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA…- benzinga.com MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of…
youtube.com MAIA: High Bar For ECB Surprise, Alphabet CAPEX In Focus: 3 Minutes MLIV Anna Edwards, Guy Johnson and Adam Linton break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade." -------- More on Bloomberg Television and Markets Like this video?
benzinga.com MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer 90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily…
globenewswire.com MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial 90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily…- benzinga.com MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
globenewswire.com MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a…
globenewswire.com MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE…
globenewswire.com MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected…
benzinga.com MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment…
globenewswire.com MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE…- benzinga.com MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDAFDA-cleared IND updates detail latest efficacy data and enriched…
globenewswire.com MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched…- benzinga.com MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were…
benzinga.com MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of…- benzinga.com MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
- benzinga.com MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial; Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage…
- benzinga.com MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of…
- benzinga.com Is the Market Bullish or Bearish on MAIA Biotechnology Inc?
benzinga.com Crude Oil Surges Over 6%; Target Profit Tops Views US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vessels. Dow down 2.45%, NASDAQ down 2.62%, S&P 500 down 2.34%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Dips 900 Points; Best Buy Posts Upbeat Earnings U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tuesday amid the ongoing Iran-U.S. conflict. Iranian state media reported that Tehran has closed the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quar- benzinga.com MAIA Biotechnology Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; No Size Disclosed MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commenced an…
- benzinga.com MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update…
- benzinga.com MAIA Biotechnology Announces $1.51M Private Placement Of 1.23M At A Price Of $1.224/Share With Warrants Exercisable At A Price Of $1.36/Share MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into…
- benzinga.com MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapyCHICAGO, Dec. 11, 2025 (GLOBE…
- benzinga.com MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and…